189 related articles for article (PubMed ID: 18581119)
21. Tissue specific expression and serum levels of human tissue factor in patients with urological cancer.
Förster Y; Meye A; Albrecht S; Kotzsch M; Füssel S; Wirth MP; Schwenzer B
Cancer Lett; 2003 Apr; 193(1):65-73. PubMed ID: 12691825
[TBL] [Abstract][Full Text] [Related]
22. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
23. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas.
Edgren M; Lennernäs B; Larsson A; Nilsson S
Anticancer Res; 1999; 19(1B):869-73. PubMed ID: 10216508
[TBL] [Abstract][Full Text] [Related]
24. Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol.
Meye A; Bilkenroth U; Schmidt U; Füssel S; Robel K; Melchior AM; Blümke K; Pinkert D; Bartel F; Linne C; Taubert H; Wirth MP
Int J Oncol; 2002 Sep; 21(3):521-30. PubMed ID: 12168095
[TBL] [Abstract][Full Text] [Related]
25. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma.
Sanders I; Holdenrieder S; Walgenbach-Brünagel G; von Ruecker A; Kristiansen G; Müller SC; Ellinger J
Int J Urol; 2012 Nov; 19(11):1017-25. PubMed ID: 22788411
[TBL] [Abstract][Full Text] [Related]
27. [Separation of urologic tumors cells from Cell Saver blood using a membrane filter. A new method in autotransfusion?].
Wiesel M; Güdemann C; Staehler G; Bierhaus A; Martin E; Hoever KH
Urologe A; 1992 May; 31(3):182-5. PubMed ID: 1615592
[TBL] [Abstract][Full Text] [Related]
28. [Tumor markers in the histopathology of urologic tumors].
Hofstädter F
Urologe A; 1987 Jan; 26(1):2-6. PubMed ID: 3576859
[TBL] [Abstract][Full Text] [Related]
29. Differences in Urinary Amino Acid Patterns in Individuals with Different Types of Urological Tumor Urinary Amino Acid Patterns as Markers of Urological Tumors.
Duskova K; Vesely S; DO Carmo Silva J; Cernei N; Zitka O; Heger Z; Adam V; Havlova K; Babjuk M
In Vivo; 2018; 32(2):425-429. PubMed ID: 29475932
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation.
Peng D; Ge G; Xu Z; Ma Q; Shi Y; Zhou Y; Gong Y; Xiong G; Zhang C; He S; He Z; Li X; Ci W; Zhou L
Epigenomics; 2018 Sep; 10(9):1189-1199. PubMed ID: 30182734
[TBL] [Abstract][Full Text] [Related]
31. Determination of serum total lipid and free N-acetylneuraminic acid in genitourinary malignancies by fluorimetric high performance liquid chromatography. Relevance of free N-acetylneuraminic acid as tumour marker.
Laganà A; Pardo-Martínez B; Marino A; Fago G; Bizzarri M
Clin Chim Acta; 1995 Dec; 243(2):165-79. PubMed ID: 8747492
[TBL] [Abstract][Full Text] [Related]
32. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and prognostic significance of preoperative plasma fibrinogen level in patients with upper urinary tract urothelial carcinoma: A retrospective tumor marker prognostic study.
Liu R; Zhou X; Zou L; Chen Q; Hu Y; Hu J; Wu X; Jiang H
Int J Surg; 2019 May; 65():88-93. PubMed ID: 30951871
[TBL] [Abstract][Full Text] [Related]
34. Elevated levels of serum aldolase A in patients with renal cell carcinoma.
Takashi M; Zhu Y; Nakano Y; Miyake K; Kato K
Urol Res; 1992; 20(4):307-11. PubMed ID: 1509638
[TBL] [Abstract][Full Text] [Related]
35. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies].
Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y
Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231
[TBL] [Abstract][Full Text] [Related]
36. [De novo urologic tumors in kidney transplant patients].
Rodríguez Faba O; Breda A; Gausa L; Palou J; Villavicencio H
Actas Urol Esp; 2015 Mar; 39(2):122-7. PubMed ID: 24996779
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.
Hayashi T; Matsubara A; Ohara S; Mita K; Hasegawa Y; Usui T; Arihiro K; Norimura S; Sentani K; Oue N; Yasui W
Oncol Rep; 2009 Jan; 21(1):95-100. PubMed ID: 19082448
[TBL] [Abstract][Full Text] [Related]
38. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin in urological malignancies.
Perabo F; Sharma S; Gierer R; Wirger A; Fimmers R; Steiner G; Adam M; Schultze-Seemann W
Indian J Cancer; 2001 Mar; 38(1):1-7. PubMed ID: 14758878
[TBL] [Abstract][Full Text] [Related]
39. Pattern of urological malignancy in Zambia. A hospital-based histopathological study.
Elem B; Patil PS
Br J Urol; 1991 Jan; 67(1):37-9. PubMed ID: 1847087
[TBL] [Abstract][Full Text] [Related]
40. Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma.
Kushlinskii NE; Gershtein ES; Morozov AA; Goryacheva IO; Filipenko ML; Alferov AA; Bezhanova SD; Bazaev VV; Kazantseva IA
Bull Exp Biol Med; 2019 Jan; 166(3):353-357. PubMed ID: 30627905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
